Crossmark

Risk factors for skeletal-related events in patients with stage IV lung adenocarcinoma and bone metastases receiving denosumab: a retrospective cohort analysis

Crossref DOI link: https://doi.org/10.1007/s00520-025-10296-0

Published Online: 2026-01-06

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Hui

Wen, Daochen

Liao, Zhou

Tan, Xiaoyong

Wang, Hao

Xiang, Jianxia

Yan, Bing
Funding

Funding for this research was provided by:

Xuanhan County Science and Technology Plan Project
License Information

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-01-06
More Information

Article History

Received: 22 June 2025

Accepted: 24 December 2025

First Online: 6 January 2026

Declarations

:

: The study protocol was approved by the Ethics Committee of Xuanhan County People’s Hospital (Approval No. 2022-KSSC-0005).

: Informed consent was obtained from all individual participants included in the study.

: This article does not involve patient privacy content.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below